UPDATED May 17, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | kr4.70 | 0% | n/a | kr2.7b | kr12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
IPHY.F | €2.20 | 0% | -24.9% | €194.8m | €5.89 | PS3.1x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$2.40 | 6.2% | 93.5% | US$286.1m | US$9.23 | PB1.6x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
0EVI | €2.41 | 5.2% | -11.4% | €194.8m | €6.27 | PS3.2x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$7.81 | 0.5% | 120.0% | US$1.8b | US$13.83 | PS11.5x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
IPHA | €2.71 | 7.1% | -7.2% | €194.8m | €7.05 | PS3.2x | E33.0% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
CSPH.F | HK$0.12 | 0% | n/a | HK$1.6b | n/a | PS3.2x | E56.9% | n/a | Pharmaceuticals & Biotech | ||
MSB | AU$1.08 | 1.4% | -4.0% | AU$1.2b | AU$1.09 | PS110.3x | E56.8% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$19.48 | 0% | n/a | HK$65.2b | HK$26.89 | PS9.7x | E50.8% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$6.06 | -3.8% | -63.2% | US$509.3m | US$14.86 | PS3x | E67.7% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$3.30 | 7.5% | 106.3% | US$119.4m | US$15.00 | PB13x | E61.8% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$46.16 | 2.6% | 853.7% | US$1.7b | US$68.14 | PB11.7x | E61.5% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$220.06 | 7.2% | -20.4% | US$4.6b | US$363.86 | PB5.5x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
0JDK | US$10.30 | -5.1% | 37.6% | US$2.9b | US$26.07 | PS1505x | E66.3% | n/a | Pharmaceuticals & Biotech | ||
CAPR | US$6.20 | 17.0% | 37.8% | US$177.7m | US$19.80 | PS7.2x | E66.2% | n/a | Pharmaceuticals & Biotech | ||
GTHX | US$4.53 | -5.0% | 58.4% | US$244.7m | US$8.50 | PS2.8x | E48.3% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$9.03 | 3.3% | 5.4% | US$881.7m | US$19.00 | PS87496.4x | E58.7% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$3.95 | 4.8% | -59.9% | US$243.0m | US$9.25 | PB2.1x | E61.1% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$8.27 | 0.1% | -27.4% | US$204.3m | US$23.24 | PS4.2x | E60.2% | n/a | Pharmaceuticals & Biotech |